The pitch to investors is simple: a ring that knows more about its wearer than the wearer does. Oura, the Finnish maker of the smart ring that tracks sleep, heart rate, and recovery, is preparing to go public in the United States as soon as September, seeking to raise up to $3 billion at a valuation above $16 billion, according to a Bloomberg report on Aug. 24. A successful listing would make Oura the most valuable wearable-device company to reach the public market, surpassing the consumer-electronics names that have preceded it.
The company’s rise has been a study in timing. Oura spent years as a niche product for athletes and biohackers, a titanium ring that promised better sleep and longer recovery, sold mostly by word of mouth. The AI era changed its math. Health data became the raw material for personalized AI, and a device worn 24 hours a day, generating continuous streams of biometrics, became the ideal sensor for models that promise to interpret what the body is doing and why.
The funding environment has cooperated as well. Investors have poured money into health technology that pairs hardware with AI, and Oura’s combination, a physical product with a subscription service and a growing software platform, has appealed to funds looking for durable revenue rather than speculative software. The company’s valuation has climbed in steps, and the $16 billion figure, if realized, would represent a substantial premium over its most recent private round.
The market for wearables has been uneven. Smartwatches dominate the category, but their growth has slowed as features have matured. Oura’s pitch is different: it does not compete on screens or apps, but on the intimacy of its data, collected from a sensor on the finger that measures temperature, pulse, and movement continuously. The company has also pushed into the enterprise market, selling rings to employers who want to monitor workforce health, a business with its own regulatory and privacy questions.
The IPO would test several assumptions at once. The first is whether the health-AI story can carry a consumer hardware company to a triple-digit valuation. The second is whether the subscription model, which turns a one-time hardware purchase into recurring revenue, can support the margins investors expect. The third is competition: Apple, Samsung, and a wave of start-ups have all introduced or are developing smart rings, and Oura’s patent position and brand remain its primary defenses.
Analysts are divided on the outlook. Bulls point to the company’s revenue growth, its high customer retention, and the expansion of its software platform into coaching and clinical partnerships. Bears note that the wearable market has a history of boom and bust, that health claims invite regulatory scrutiny, and that the valuation implies the company will hold its lead against the largest hardware companies in the world.
The September timeline matters. The window for technology IPOs has been open, with investors hungry for new listings after a long drought, and Oura wants to ride the momentum before the market’s attention shifts. The company has been meeting with prospective investors, according to people familiar with the process, and its roadshow materials emphasize the shift from selling hardware to selling a health service.
The company’s history is a lesson in persistence. Oura was founded in 2013, before the health-tracking wave and long before AI became the industry’s favorite adjective. Its early years were lean, and the ring spent years as a niche product with a devoted following. The breakthrough came when the company paired its hardware with a subscription service and then with AI-powered insights, turning a device that recorded data into a service that interpreted it. The evolution from hardware company to health-data company is central to its IPO story, and to its valuation.
The IPO market’s mood will matter as much as the company’s numbers. The window for new listings has been open, but it has been selective, with investors rewarding companies that can show a clear path to profit. Oura’s path runs through subscriptions, which now account for a growing share of its revenue, and through partnerships with health systems and employers. The company has argued that its data, collected continuously and privately, will become more valuable as AI models improve, and that its ring is the sensor those models will depend on.
Privacy will be a theme of the roadshow, and a risk for the stock. Health data is among the most sensitive categories of personal information, and Oura’s collection of biometrics, sleep patterns, and heart data has already drawn questions from regulators in Europe and the United States. The company’s answers, and its compliance record, will be scrutinized by investors who have watched health-technology stocks fall on privacy concerns. The ring’s promise, to know its wearer better than anyone, cuts both ways.
The outcome will also be read as a verdict on the broader category. If Oura prices at a premium and trades higher, it will open the door for other health-wearable companies to test the market. If it stumbles, the smart-ring sector, and the health-AI hardware wave more broadly, will find the door harder to open. The ring that knows everything about its wearer is about to learn what the market thinks of it.
